ADAR1 Capital Management LLC Invests $1.74 Million in Palvella Therapeutics (NASDAQ:PVLA)

ADAR1 Capital Management LLC bought a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 144,641 shares of the company’s stock, valued at approximately $1,736,000. ADAR1 Capital Management LLC owned about 1.29% of Palvella Therapeutics at the end of the most recent quarter.

Separately, Geode Capital Management LLC purchased a new position in shares of Palvella Therapeutics in the fourth quarter worth approximately $171,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $23.98 on Monday. The business has a 50 day moving average price of $21.48. The company has a market capitalization of $264.24 million, a PE ratio of -1.98 and a beta of 0.10. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $29.27.

Wall Street Analyst Weigh In

PVLA has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, April 1st. Jones Trading assumed coverage on Palvella Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $45.00 price objective for the company. TD Cowen started coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price for the company. Canaccord Genuity Group restated a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $43.50.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.